Evaluation of the Immunological Response of Childhood Cancer Patients Treated with a Personalized Peptide Vaccine for Refractory Soft Tissue Tumor: A Four-Case Series-Reference-Cited by-同舟云学术

Evaluation of the Immunological Response of Childhood Cancer Patients Treated with a Personalized Peptide Vaccine for Refractory Soft Tissue Tumor: A Four-Case Series

Published:2021-06-30 Issue:2 Volume:68 Page:157-163
ISSN:0023-5679
Container-title:The Kurume Medical Journal
language:en
Short-container-title:Kurume Med. J.

Author:

ODA KEIKO¹,ITO YASUHIKO²,YAMADA AKIRA¹,YUTANI SHIGERU¹,ITOH KYOGO¹,OZONO SHUICHI³

Affiliation:

1. Kurume University Cancer Vaccine Center

2. Department of Pediatrics, Nagoya City University

3. Department of Pediatrics, Kurume University School of Medicine

Publisher

Kurume Medical Journal

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/kurumemedj/68/2/68_MS682012/_pdf

Reference20 articles.

1. 1. Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S et al. ACCELERATE and European medicines agency paediatric strategy forum for medicinal product development of checkpoint inhibitors for using combination therapy in paediatric patients. Eur J Cancer 2020; 127:52-66.

2. 2. Siegel RL, Miller KD, and Jemel A. Cancer statics, 2020. CA Cancer J Clin 2020; 70:7-30.

3. 3. PDQ^® Pediatric Treatment Editorial Board. PDQ cancer Information Summaries [Internet]. Late effect pf treatment. Bethesada (MD), National Cancer Institute 2002-2020.

4. 4. Leung W, Naele G, Behm F, Iyengar R, Finkelstein D et al. Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol 2010; 34:303-308.

5. 5. Takahashi R, Ishibashi Y, Hiraoka K, Matsueda S, Kawano K et al. Phase Ⅱ study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Sci 2013; 104:1285-1294.